Demonstrating Fragment-Based Drug Discovery of ASTX029, a Dual Mechanism ERK1/2 Inhibitor

Time: 2:45 pm
day: Day 2 Track A PM


  • Describing the fragment-based drug discovery of ASTX029, a dual-mechanism ERK1/2 (ERK) inhibitor that suppresses both the catalytic activity and phosphorylation of ERK
  • Highlighting the opportunity that ASTX029 offers as a potent inhibitor of MAPK-activated tumor growth in preclinical models
  • Showcasing ASTX029, which is currently undergoing clinical development in a Ph1/2 trial in advanced solid tumors